TMS-007 is a Small Molecule owned by Biogen, and is involved in 1 clinical trial, which is planned.
TMS-007 acts by inhibiting soluble epoxide hydrolase (sEH) and acts to relax the conformation of plasminogen. SMTP-7 by inhibiting both of the two sEH enzyme activities epoxide hydrolase and lipid phosphate phosphatase results in inhibition in the anti-inflammatory mechanism. SMTP-7 promotes plasminogen activator-catalyzed plasminogen activation by modulating its conformation. The activity of SMTP-7 is attributable to an anti-inflammatory action as well as thrombolysis due to plasminogen modulation. TMS-007 by inhibiting soluble epoxide hydrolase (sEH) and activating plasminogen exhibits its therapeutic intervention.
The revenue for TMS-007 is expected to reach a total of $3.8bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the TMS-007 NPV Report.
TMS-007 is currently owned by Biogen.
TMS-007 (Stachybotrys microspora triprenyl phenol-7) is under development for the treatment of acute ischemic stroke. The drug candidate is administered through intravenous route. The drug candidate is produced from the culture of the filamentous fungus Stachybotrys microspora (SM) and has a structure of triprenyl phenol (TP). The drug candidate acts by targeting soluble epoxide hydrolase (sEH) and plasminogen.
Biogen is a biopharmaceutical company that discovers, develops, and delivers drugs and biosimilars for the treatment of various neurological and neurodegenerative diseases. The company’s marketed products include Avonex (interferon beta-1a), Tysabri (natalizumab), Tecfidera (dimethyl fumarate), Fampyra (prolonged-release fampridine tablets), and Plegridy (peginterferon beta-1a) for the treatment of multiple sclerosis (MS); Spinraza (nusinersen) for spinal muscular atrophy (SMA); and Fumaderm (fumaric acid esters) for severe plaque psoriasis. It has several product candidates targeting various indications such as MS, Parkinson’s disease, CNS and neuromuscular disorders, Alzheimer’s disease, and idiopathic pulmonary fibrosis and stroke. The company sells its products through direct sales force, marketing groups, and distributors in the Americas, Europe, Asia, and other territories. Biogen is headquartered in Cambridge, Massachusetts, the US.
The company reported revenues of (US Dollars) US$10,981.7 million for the fiscal year ended December 2021 (FY2021), a decrease of 18.3% over FY2020. In FY2021, the company’s operating margin was 25.9%, compared to an operating margin of 33.8% in FY2020. In FY2021, the company recorded a net margin of 14.2%, compared to a net margin of 29.8% in FY2020. The company reported revenues of US$2,508.5 million for the third quarter ended September 2022, a decrease of 3.1% over the previous quarter.
Quick View – TMS-007
|Highest Development Stage|